DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,955,813 B2 De Kreijet Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,955,813 B2 De Kreijet Al US007955813B2 (12) United States Patent (10) Patent No.: US 7,955,813 B2 De Kreijet al. (45) Date of Patent: *Jun. 7, 2011 (54) METHOD OF USING LIPID 3,939,350 A 2f1976 Kronicket al. ACYLTRANSFERASE 3,973,042 A 8, 1976 Kosikowski 3.996,345 A 12/1976 Ullman et al. 4,034,124 A 7, 1977 Van Dam (75) Inventors: Arno De Kreij, Papendrecht (NL); 4,065,580 A 12/1977 Feldman Susan Mampusti Madrid, Vedbaek 4,160,848 A T. 1979 Vidal 4,202,941 A 5/1980 Terada (DK); Jorn Dalgaard Mikkelsen, 4,275,149 A 6/1981 Litman et al. Hvidovre (DK); Jorn Borch Soe, Tilst 4,277.437 A 7/1981 Maggio (DK) 4,366,241 A 12/1982 Tom et al. 4,399.218 A 8, 1983 Gauhl (73) Assignee: Danisco, A/S, Copenhagen (DK) 4,567.046 A 1/1986 Inoue 4,683.202 A 7, 1987 Mullis 4,689,297 A 8, 1987 Good (*) Notice: Subject to any disclaimer, the term of this 4,707,291 A 11, 1987 Thom patent is extended or adjusted under 35 4,707,364 A 11/1987 Barach U.S.C. 154(b) by 1056 days. 4,708,876 A 1 1/1987 Yokoyama 4,798,793 A 1/1989 Eigtved This patent is Subject to a terminal dis 4,808,417 A 2f1989 Masuda claimer. 4,810,414 A 3/1989 Huge-Jensen 4,814,331 A 3, 1989 Kerkenaar 4,816,567 A 3/1989 Cabilly et al. (21) Appl. No.: 11/483,345 4,818,695 A 4/1989 Eigtved 4,826,767 A 5/1989 Hansen (22) Filed: Jul. 7, 2006 4,865,866 A 9, 1989 Moore 4,904.483. A 2f1990 Christensen (65) Prior Publication Data 4,916,064 A 4, 1990 Derez 5,112,624 A 5/1992 Johna US 2007/0026106A1 Feb. 1, 2007 5,213,968 A 5, 1993 Castle 5,219,733 A 6/1993 Myojo 5,219,744 A 6/1993 Kurashige Related U.S. Application Data 5,232,846 A 8, 1993 Takeda (63) Continuation of application No. 1 1/182,408, filed on 5,264,367 A 11/1993 Aalrust 5,273,898 A 12, 1993 Ishii Jul. 15, 2005, now Pat. No. 7,807,398, which is a 5,288,619 A 2f1994 Brown continuation-in-part of application No. 5,290,694 A 3, 1994 Nakanishi PCT/IB2004/000655, filed on Jan. 15, 2004. 5,310,679 A 5/1994 Artiss et al. (60) Provisional application No. 60/489.441, filed on Jul. (Continued) 23, 2003. FOREIGN PATENT DOCUMENTS (30) Foreign Application Priority Data AR 331094 2, 1995 (Continued) Jan. 17, 2003 (GB) ................................... O3O1117.8 Jan. 17, 2003 (GB) ...... ... O3O1118.6 OTHER PUBLICATIONS Jan. 17, 2003 (GB) ...... ... O301 1194 Jan. 17, 2003 (GB) ...... ... O3O112O2 Fernandez-Garcia et al. J. Dairy Sci. 77: 2139-2149 (1994).* Jan. 17, 2003 (GB) ...... ... O3O1121.0 Jan. 17, 2003 (GB) ...... ... O3O1122.8 (Continued) Dec. 24, 2003 (GB) ................................... O33OO16.7 Primary Examiner — Tekchand Saidha (51) Int. Cl. (74) Attorney, Agent, or Firm — Vedder Price P.C.; Thomas CI2O I/48 (2006.01) J. Kowalski; Heidi Lunasin CI2N 9/10 (2006.01) (52) U.S. Cl. ............................. 435/15; 435/49; 435/193 (57) ABSTRACT (58) Field of Classification Search .................. 435/193, A method for the in situ production of an emulsifier in a 435/15, 49 foodstuff, wherein a lipid acyltransferase is added to the See application file for complete search history. foodstuff. Preferably the emulsifier is produced without an increase or without a substantial increase in the free fatty acid (56) References Cited content of the foodstuff. Preferably, the lipid acyltransferase is one which is capable of transferring an acyl group from a U.S. PATENT DOCUMENTS lipid to one or more of the following acyl acceptors: a sterol, 2,888,385 A 5, 1959 Grandel 3.260,606 A 7, 1966 AZuma. a stanol, a carbohydrate, a protein or a sub-unit thereof glyc 3.368,903. A 2f1968 Johnson erol. Preferably, in addition to an emulsifier one or more of a 3,520,702 A 7, 1970 Menzi stanol ester or a stanol ester or a protein ester or a carbohy 3,634,195 A 1/1972 Melachouris drate ester or a diglyceride or a monoglyceride may be pro 3.652,397 A 3, 1972 Pardun 3,677,902 A 7, 1972 Aunstrup duced. One or more of these may function as an additional 3,817,837 A 6, 1974 Rubenstein et al. emulsifier. 3,850,752 A 11/1974 Wilhelmus et al. 3,852,260 A 12/1974 Knutsen 26 Claims, 66 Drawing Sheets US 7,955,813 B2 Page 2 U.S. PATENT DOCUMENTS 2002/016874.6 A1 11/2002 Tsutsumi 2002/0182734 A1 12/2002 Diaz-Torres 5,378,623. A 1/1995 Hattori 2003,0003561 A1 1/2003 Vind 5,523,237 A 6/1996 Budtz 2003/0028923 A1 2/2003 Lardizabal 5,536,661. A 7/1996 Boel 2003/0040450 A1 2/2003 Rey 5,558,781. A 9/1996 Buchold 2003/0074695 A1 4, 2003 Farese 39); A 1887 Abs al 2003.01.00092 A1 5.2003 Berka 5677:160 A 10/1997 St 2003/01 19164 A1 6/2003 Udagawa 5,695,802 A 12/1997 Van Den Ouweland 58,862 A. 838. sup 5,716,654. A 2, 1998 Groenendaal 2003.0185939 A1 10, 2003 Nielsen 5,741,665 A 4, 1998 Kato et al. 2003/0215544 A1 11/2003 Nielsen 5,763,383. A 6/1998 Hashida 2004.0005399 A1 1/2004 Chakrabart 5,766,912 A 6/1998 Boel 2004/0142441 A1 7/2004 Weiss et al. 5,776,741. A 7/1998 Pedersen 2004/023510.6 A1 1 1/2004 Kapeller-Libermann 5,814,501. A 9, 1998 Becker 2004/02351 19 A1 1 1/2004 Hoppe et al. 35-3A 1998 E. al 2005/005913.0 A1 3/2005 Bojsen 5827.719 A 10/1998 st 2005/0059131 A1 3/2005 Bisgard-Frantzen wa. 2005, 0118697 A1 6, 2005 Budolfsen SSA 3. t 2005. O142647 A1 6, 2005 Wassell 5.856,163 A 1, 1999 E. G 2006/0040357 A1 2/2006 Bandaru et al. w - w 2006.0075518 A1 4, 2006 Yaver et al. 5,863,759 A 1/1999 Boel 2006/0141457 A1 6/2006 Lindqvist et al. 5,869,438 A 3229 Sydsen 2007/0026106 A1 2/2007 Kreijet al. 375. A SE S. 2007/0122525A1 5/2007 Krei 5892.013 A 4, 1999 S.dsen 2008/0063783 A1 3/2008 Kreijet al. 5914306 A 6/1999 Svendsen 2008.0070287 A1 3, 2008 Soe 596,619. A 6/1999 Miyazaki 2008/013 1936 A1 6/2008 Miasnikow et al. 5.99.746 A 7/1999 Hirayama 2008. O187643 A1 8, 2008 Horlacher SE A 1999 Sysen FOREIGN PATENT DOCUMENTS 5,965,422 A 10/1999 Loffler AR 249546 12/1996 5,976,855. A 1 1/1999 Svendsen AR POOO 105426 10, 2000 5,989,599 A 1 1/1999 Chmiel AR P040 101441 4/2004 5.990,069 A 1 1/1999 Andre AT 110 768 8, 1987 6,001.586 A 12/1999 Schellenberger AU 570720 9, 1984 6,001,640 A 12/1999 Loeffler AU T23031 4f1998 6,020, 180 A 2/2000 Svendsen AU 75447O 11, 1999 6,066,482. A 5/2000 Steffens et al. BR 8404421-7 4f1984 6,074,863 A 6/2000 Svendsen CA 127O781 6, 1990 6,103,505. A 8/2000 Clausen CA 2012723 9, 1990 6,110,508 A 8/2000 Olesen CA 2134597 10, 1994 6,140,094. A 10/2000 Loffler CA 2224143 12/1996 6,143,543 A 1 1/2000 Michelsen CA 2403 O25 4/2004 6,143,545. A 1 1/2000 Clausen CA 2403025 4/2004 6,146,869 A 1 1/2000 Harris CN O36151 2, 2002 6,156,548. A 12/2000 Christensen CN 1725O9 6, 2003 6,180,406 B1 1/2001 Stemmer CN 97817O6.5 10, 2003 6,254,645 B1 7/2001 Kellis CN 97181706.5 10, 2003 6,254,903 B1 7/2001 Schuster et al. CN 101.200754 12/2007 6,344,328 B1 2/2002 Short DE 2817087 11, 1978 6.350,604 B1 2/2002 Hirayama DE 1962O649 11, 1997 6,358,543 B1 3/2002 Soe DE 69 129988 3, 1999 6,361974 B1 3/2002 Short DE 6933OO66 10, 2001 6,365,204 B1 4/2002 Spendler DE 101 19972 5, 2002 6.432,898 B1 8/2002 Rey DE 695.27835 4/2003 6,495.357 B1 12/2002 Fuglsang DE 69528070 6, 2003 6,506,588 B2 1/2003 Tsutsumi DE 69333065 T 2003 6,509, 182 B2 1/2003 Tsutsumi DE 69904161 T 2003 6,511,837 B2 1/2003 Tsutsumi DE 697.16711 9, 2003 6,514,739 B1 2/2003 Udagawa DE 69333065 4/2004 6,558,715 B1 5/2003 Rey DE 69531538 6, 2004 6,582,942 B1 6/2003 Christensen DE 698.19782 9, 2004 6,624,129 B1 9/2003 Borch DK 3106.200 1, 1989 6,645,749 B2 11/2003 Vind DK 157560 1, 1990 6,682,922 B2 1/2004 Berka DK PAO888/92 7, 1992 6,686,189 B2 2/2004 Rey DK O217.94 2, 1994 6,726,942 B2 4/2004 Soe et al. DK PAO830.95 7, 1995 6,730,346 B2 5/2004 Rey DK PA1096.95 9, 1995 6,815, 190 B1 1 1/2004.
Load more

Recommended publications
  • ATP-Citrate Lyase Has an Essential Role in Cytosolic Acetyl-Coa Production in Arabidopsis Beth Leann Fatland Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2002 ATP-citrate lyase has an essential role in cytosolic acetyl-CoA production in Arabidopsis Beth LeAnn Fatland Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Molecular Biology Commons, and the Plant Sciences Commons Recommended Citation Fatland, Beth LeAnn, "ATP-citrate lyase has an essential role in cytosolic acetyl-CoA production in Arabidopsis " (2002). Retrospective Theses and Dissertations. 1218. https://lib.dr.iastate.edu/rtd/1218 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. ATP-citrate lyase has an essential role in cytosolic acetyl-CoA production in Arabidopsis by Beth LeAnn Fatland A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Plant Physiology Program of Study Committee: Eve Syrkin Wurtele (Major Professor) James Colbert Harry Homer Basil Nikolau Martin Spalding Iowa State University Ames, Iowa 2002 UMI Number: 3158393 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted.
    [Show full text]
  • TRP Channel Transient Receptor Potential Channels
    TRP Channel Transient receptor potential channels TRP Channel (Transient receptor potential channel) is a group of ion channels located mostly on the plasma membrane of numerous human and animal cell types. There are about 28 TRP channels that share some structural similarity to each other. These are grouped into two broad groups: Group 1 includes TRPC ("C" for canonical), TRPV ("V" for vanilloid), TRPM ("M" for melastatin), TRPN, and TRPA. In group 2, there are TRPP ("P" for polycystic) and TRPML ("ML" for mucolipin). Many of these channels mediate a variety of sensations like the sensations of pain, hotness, warmth or coldness, different kinds of tastes, pressure, and vision. TRP channels are relatively non-selectively permeable to cations, including sodium, calcium and magnesium. TRP channels are initially discovered in trp-mutant strain of the fruit fly Drosophila. Later, TRP channels are found in vertebrates where they are ubiquitously expressed in many cell types and tissues. TRP channels are important for human health as mutations in at least four TRP channels underlie disease. www.MedChemExpress.com 1 TRP Channel Inhibitors, Antagonists, Agonists, Activators & Modulators (-)-Menthol (E)-Cardamonin Cat. No.: HY-75161 ((E)-Cardamomin; (E)-Alpinetin chalcone) Cat. No.: HY-N1378 (-)-Menthol is a key component of peppermint oil (E)-Cardamonin ((E)-Cardamomin) is a novel that binds and activates transient receptor antagonist of hTRPA1 cation channel with an IC50 potential melastatin 8 (TRPM8), a of 454 nM. Ca2+-permeable nonselective cation channel, to 2+ increase [Ca ]i. Antitumor activity. Purity: >98.0% Purity: 99.81% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg, 1 g Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg (Z)-Capsaicin 1,4-Cineole (Zucapsaicin; Civamide; cis-Capsaicin) Cat.
    [Show full text]
  • Regulation of TRP Channels by Steroids
    General and Comparative Endocrinology xxx (2014) xxx–xxx Contents lists available at ScienceDirect General and Comparative Endocrinology journal homepage: www.elsevier.com/locate/ygcen Review Regulation of TRP channels by steroids: Implications in physiology and diseases ⇑ Ashutosh Kumar, Shikha Kumari, Rakesh Kumar Majhi, Nirlipta Swain, Manoj Yadav, Chandan Goswami School of Biology, National Institute of Science Education and Research, Sachivalaya Marg, Bhubaneswar, Orissa 751005, India article info abstract Article history: While effects of different steroids on the gene expression and regulation are well established, it is proven Available online xxxx that steroids can also exert rapid non-genomic actions in several tissues and cells. In most cases, these non-genomic rapid effects of steroids are actually due to intracellular mobilization of Ca2+- and other ions Keywords: suggesting that Ca2+ channels are involved in such effects. Transient Receptor Potential (TRP) ion TRP channels channels or TRPs are the largest group of non-selective and polymodal ion channels which cause Ca2+- Steroids influx in response to different physical and chemical stimuli. While non-genomic actions of different Non-genomic action of steroids steroids on different ion channels have been established to some extent, involvement of TRPs in such Ca2+-influx functions is largely unexplored. In this review, we critically analyze the literature and summarize how Expression different steroids as well as their metabolic precursors and derivatives can exert non-genomic effects by acting on different TRPs qualitatively and/or quantitatively. Such effects have physiological repercus- sion on systems such as in sperm cells, immune cells, bone cells, neuronal cells and many others.
    [Show full text]
  • Structural Basis for Human Sterol Isomerase in Cholesterol Biosynthesis and Multidrug Recognition
    ARTICLE https://doi.org/10.1038/s41467-019-10279-w OPEN Structural basis for human sterol isomerase in cholesterol biosynthesis and multidrug recognition Tao Long 1, Abdirahman Hassan 1, Bonne M Thompson2, Jeffrey G McDonald1,2, Jiawei Wang3 & Xiaochun Li 1,4 3-β-hydroxysteroid-Δ8, Δ7-isomerase, known as Emopamil-Binding Protein (EBP), is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis, autophagy, 1234567890():,; oligodendrocyte formation. The mutation on EBP can cause Conradi-Hunermann syndrome, an inborn error. Interestingly, EBP binds an abundance of structurally diverse pharmacolo- gically active compounds, causing drug resistance. Here, we report two crystal structures of human EBP, one in complex with the anti-breast cancer drug tamoxifen and the other in complex with the cholesterol biosynthesis inhibitor U18666A. EBP adopts an unreported fold involving five transmembrane-helices (TMs) that creates a membrane cavity presenting a pharmacological binding site that accommodates multiple different ligands. The compounds exploit their positively-charged amine group to mimic the carbocationic sterol intermediate. Mutagenesis studies on specific residues abolish the isomerase activity and decrease the multidrug binding capacity. This work reveals the catalytic mechanism of EBP-mediated isomerization in cholesterol biosynthesis and how this protein may act as a multi-drug binder. 1 Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 2 Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 3 State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China. 4 Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,906,307 B2 S0e Et Al
    US007906307B2 (12) United States Patent (10) Patent No.: US 7,906,307 B2 S0e et al. (45) Date of Patent: Mar. 15, 2011 (54) VARIANT LIPIDACYLTRANSFERASES AND 4,683.202 A 7, 1987 Mullis METHODS OF MAKING 4,689,297 A 8, 1987 Good 4,707,291 A 11, 1987 Thom 4,707,364 A 11/1987 Barach (75) Inventors: Jorn Borch Soe, Tilst (DK); Jorn 4,708,876 A 1 1/1987 Yokoyama Dalgaard Mikkelson, Hvidovre (DK); 4,798,793 A 1/1989 Eigtved 4,808,417 A 2f1989 Masuda Arno de Kreij. Geneve (CH) 4,810,414 A 3/1989 Huge-Jensen 4,814,331 A 3, 1989 Kerkenaar (73) Assignee: Danisco A/S, Copenhagen (DK) 4,818,695 A 4/1989 Eigtved 4,826,767 A 5/1989 Hansen 4,865,866 A 9, 1989 Moore (*) Notice: Subject to any disclaimer, the term of this 4,904.483. A 2f1990 Christensen patent is extended or adjusted under 35 4,916,064 A 4, 1990 Derez U.S.C. 154(b) by 0 days. 5,112,624 A 5/1992 Johna 5,213,968 A 5, 1993 Castle 5,219,733 A 6/1993 Myojo (21) Appl. No.: 11/852,274 5,219,744 A 6/1993 Kurashige 5,232,846 A 8, 1993 Takeda (22) Filed: Sep. 7, 2007 5,264,367 A 11/1993 Aalrust (Continued) (65) Prior Publication Data US 2008/OO70287 A1 Mar. 20, 2008 FOREIGN PATENT DOCUMENTS AR 331094 2, 1995 Related U.S. Application Data (Continued) (63) Continuation-in-part of application No.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,642,021 B2 Brautigam Et Al
    USOO8642021B2 (12) United States Patent (10) Patent No.: US 8,642,021 B2 Brautigam et al. (45) Date of Patent: *Feb. 4, 2014 (54) CONDITIONING COMPOSITION FOR HAIR FOREIGN PATENT DOCUMENTS (75) Inventors: Ina Brautigam, Darmstadt (DE); Frank DE 2630560 1/1978 ............... A61K 7.48 EP O315541 5, 1989 ............... A61K 7.48 Hermes, Seeheim (DE) FR 241 1001 7, 1979 ............... A61K 700 JP O7327633. A * 12/1995 (73) Assignee: Kao Germany GmbH, Darmstadt (DE) WO WOOO28966 A1 * 5, 2000 WO WOO3,070208 A1 8/2003 ............. A61K 7,134 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 1520 days. Abstract Accession No. 2000:35.1345 from the CaPlus database on This patent is Subject to a terminal dis STN, the bibliography, abstract and indexing data for WO 200028966 claimer. A1, downloaded on Aug. 8, 2007, 2 pages.* Quest International: “Yogurtene” Cosmetic Ingredients (Jun. 2000) (21) Appl. No.: 11/001,840 pp. 1-17.* Machine translation of JP 07327633A dowloaded from the JPO Feb. (22) Filed: Dec. 2, 2004 14, 2012.* thehealthyeating.org website (www.healthyeating.org/Milk-Dairy/ (65) Prior Publication Data Nutrients-in-Milk-Cheese-Yogurt/Yogurt-Nutrition. aspx?Referer-dairycouncilofca (downloaded Feb. 28, 2013).* US 2005/O152863 A1 Jul. 14, 2005 Website: Clairol's Touch of Yoghurt Shampoo (http://brandfailures. (30) Foreign Application Priority Data blogspot.com/2006/12/other-famous-brand-idea-failures.html) downloaded Feb. 28, 2013).* Skin Deep website http://www.ewg.org/skindeepfingredient/ Dec. 5, 2003 (EP) ..................................... O3O27985 702759/GUAR HYDROXYPROPYLTRIMONIUM CHLO RIDE/downloaded Sep.
    [Show full text]
  • (12)UK Patent Application (1S1GB ,„>2577037 ,,3,A 2577037
    (12)UK Patent Application (1S1GB ,„>2577037 ,,3,A (43) Date of A Publication 18.03.2020 (21) Application No: 1812997.3 (51) INT CL: C12N 15/52 (2006.01) C12P 33/02 (2006.01) (22) Date of Filing: 09.08.2018 C12R 1/32 (2006.01) C12R 1/365 (2006.01) (56) Documents Cited: GB 2102429 A EP 3112472 A (71) Applicant(s): WO 2001/031050 A US 4345029 A Cambrex Karlskoga AB US 4320195 A (Incorporated in Sweden) Appl Environ Microbiol, published online 4 May 2018, S-691 85 Karlskoga, Sweden Liu et al, "Characterization and engineering of 3- ketosteroid 9a-hydroxylases in Mycobacterium Rijksuniversiteit Groningen neoarum ATCC 25795 for the development of (Incorporated in the Netherlands) androst-1,4- diene3,17-dione and 9a-hydroxy- Broerstraat 5, 9712 CP Groningen, Netherlands androst-4-ene-3,17-dione-producing strains" Appl Environ Microbiol, Vol 77 (2011), Wilbrink et al, (72) Inventor(s): "FadD19 of Rhodococcus rhodochrous DMS43269, a Jonathan Knight steroid-coenzyme A ligase essential for degradation Cecilia Kvarnstrom Branneby of C-24 branched sterol side chains", pp 4455-4464 Lubbert Dijkhuizen FEMS Microbiol Letts, Vol 205 (2001), van der Geize et Janet Maria Petrusma al, "Unmarked gene deletion mutagenesis of kstD, Laura Fernandez De Las Heras encoding 3-ketosteroid deltal-dehydrogenase, in Rhodococcus erythropolis SQ1 using sacB as a counter-selectable marker", pp 197-202 (74) Agent and/or Address for Service: J Steroid Biochem Mol Biol, Vol 172 (2017), Guevara Potter Clarkson LLP et al, "Functional characterization of 3-ketosteroid 9a- The
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Zheng Zhao, Delft University of Technology Marcel A. van den Broek, Delft University of Technology S. Aljoscha Wahl, Delft University of Technology Wilbert H. Heijne, DSM Biotechnology Center Roel A. Bovenberg, DSM Biotechnology Center Joseph J. Heijnen, Delft University of Technology An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Marco A. van den Berg, DSM Biotechnology Center Peter J.T. Verheijen, Delft University of Technology Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. PchrCyc: Penicillium rubens Wisconsin 54-1255 Cellular Overview Connections between pathways are omitted for legibility. Liang Wu, DSM Biotechnology Center Walter M. van Gulik, Delft University of Technology L-quinate phosphate a sugar a sugar a sugar a sugar multidrug multidrug a dicarboxylate phosphate a proteinogenic 2+ 2+ + met met nicotinate Mg Mg a cation a cation K + L-fucose L-fucose L-quinate L-quinate L-quinate ammonium UDP ammonium ammonium H O pro met amino acid a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar a sugar K oxaloacetate L-carnitine L-carnitine L-carnitine 2 phosphate quinic acid brain-specific hypothetical hypothetical hypothetical hypothetical
    [Show full text]
  • SANTOS, GABRIELA TREVISAN DOS.Pdf (5.044Mb)
    UNIVERSIDADE FEDERAL DE SANTA MARIA CENTRO DE CIÊNCIAS NATURAIS E EXATAS PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS BIOLÓGICAS: BIOQUÍMICA TOXICOLÓGICA CARACTERIZAÇÃO DO ESTERÓIDE α-ESPINASTEROL COMO UM NOVO ANTAGONISTA DO RECEPTOR TRPV1 COM EFEITO ANTINOCICEPTIVO DISSERTAÇÃO DE MESTRADO Gabriela Trevisan dos Santos Santa Maria, RS, Brasil 2011 α CARACTERIZAÇÃO DO ESTERÓIDE -ESPINASTEROL COMO UM NOVO ANTAGONISTA DO RECEPTOR TRPV1 COM EFEITO ANTINOCICEPTIVO Por Gabriela Trevisan dos Santos Dissertação apresentada ao curso de Mestrado do Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica da Universidade Federal de Santa Maria (UFSM, RS), como requisito parcial para obtenção do grau de Mestre em Ciências Biológicas: Bioquímica Toxicológica. Orientador: Prof. Dr. Juliano Ferreira Santa Maria, RS, Brasil 2011 Universidade Federal de Santa Maria Centro de Ciências Naturais e Exatas Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica A comissão examinadora, abaixo assinada, Aprova a Dissertação de Mestrado CARACTERIZAÇÃO DO ESTERÓIDE α-ESPINASTEROL COMO UM NOVO ANTAGONISTA DO RECEPTOR TRPV1 COM EFEITO ANTINOCICEPTIVO elaborada por Gabriela Trevisan dos Santos Como requisito parcial para obtenção do grau de Mestre em Ciências Biológicas: Bioquímica Toxicológica COMISSÃO EXAMINADORA ___________________________________ Juliano Ferreira, Dr. (Orientador) ________________________________ Maria Rosa Chitolina Schetinger, Dra. (UFSM) ___________________________________ Roselei Fachinetto, Dra. (UFSM) Santa Maria, 1 de Setembro de 2011 AGRADECIMENTOS Agradeço a Deus por iluminar meu caminho e me dar forças para seguir sempre em frente. Aos meus familiares, em especial, a meus pais Joaquim e Claudia, e ao meu irmão Guilherme, pelo apoio incondicional, o que contribuiu para que todos os momentos difíceis se tornassem passageiros. Ao meu orientador, Juliano Ferreira, pela oportunidade oferecida, pelos conselhos, ensinamentos e principalmente pelo bom convívio em todos estes anos de trabalho.
    [Show full text]
  • Iminosugar-Steroid Conjugates As Potential Α-Glycosidase Inhibitors and Antiproliferative Agents
    UNIVERSIDADE DA BEIRA INTERIOR Ciências Iminosugar-steroid conjugates as potential α-glycosidase inhibitors and antiproliferative agents Sara Cristina Nobre Garcia Dissertação para obtenção do Grau de Mestre em Química Medicinal (2º ciclo de estudos) Orientador: Prof. Doutor Samuel Martins Silvestre Co-orientador: Prof. Doutor Carmen Ortiz Mellet Covilhã, junho de 2016 ii À minha irmã, a minha versão mais velha, mas o (meu) modelo a seguir. iii iv Agradecimentos/Acknowledgements Em primeiro lugar gostaria de agradecer ao Professor Doutor Samuel Silvestre por ter possibilitado o desenvolvimento deste projeto, e ainda toda a orientação, paciência, confiança e disponibilidade ao longo de todo o ano. Also, I want to thank to Cathedratic Professor Carmen Ortiz Mellet for allowing to carry out the organic synthesis of this project in her investigation group on Departamento de Quimica Organica of Universidad de Sevilla, and to Doctor Elena Sáchez-Fernández for the assisting and help during the whole period. I am grateful for the reception and mutual aid that I found in the group. Especially, I want to thank to Doctor Rita Pereira who always was present from the first year of my bachelor until this moment, even more in the course of this project, helping me as much as possible. Agradeço a todas as minhas colegas de laboratório no Centro de Investigação em Ciências da Saúde-UBI, principalmente à Mariana Matias, Sandrina Maçãs, Elisabete Alves, Mafalda Catarro, Ângela Gonçalves e Vanessa de Brito por tudo o que ensinaram e auxiliaram e claro, pelos bons momentos passados. Agradeço aos meus pais, avó e irmãos que tornaram todo este caminho possível, e ainda a todos os outros familiares e amigos que me apoiaram durante todo o meu percurso académico.
    [Show full text]
  • WO 2010/067327 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 17 June 2010 (17.06.2010) WO 2010/067327 Al (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, C08B 37/00 (2006.01) A61K 8/73 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/IB2009/055663 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 10 December 2009 (10.12.2009) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (25) Filing Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 0858501 11 December 2008 ( 11.12.2008) FR GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (71) Applicant (for all designated States except US): SEDER- TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, MA [FR/FR]; 29 rue du Chemin Vert, F-78610 Le Perray ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, en Yvelines (FR).
    [Show full text]
  • Patent Application Publication (10) Pub. No.: US 2009/0131395 A1 Antonelli Et Al
    US 20090131395A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0131395 A1 Antonelli et al. (43) Pub. Date: May 21, 2009 (54) BIPHENYLAZETIDINONE CHOLESTEROL Publication Classification ABSORPTION INHIBITORS (51) Int. Cl. (75) Inventors: Stephen Antonelli, Lynn, MA A 6LX 3L/397 (2006.01) (US); Regina Lundrigan, C07D 205/08 (2006.01) Charlestown, MA (US); Eduardo J. A6IP 9/10 (2006.01) Martinez, St. Louis, MO (US); Wayne C. Schairer, Westboro, MA (52) U.S. Cl. .................................... 514/210.02:540/360 (US); John J. Talley, Somerville, MA (US); Timothy C. Barden, Salem, MA (US); Jing Jing Yang, (57) ABSTRACT Boxborough, MA (US); Daniel P. The invention relates to a chemical genus of 4-biphenyl-1- Zimmer, Somerville, MA (US) phenylaZetidin-2-ones useful in the treatment of hypercho Correspondence Address: lesterolemia and other disorders. The compounds have the HESLN ROTHENBERG EARLEY & MEST general formula I: PC S COLUMBIA. CIRCLE ALBANY, NY 12203 (US) (73) Assignee: MICROBIA, INC., Cambridge, MA (US) “O O (21) Appl. No.: 11/913,461 o R2 R4 X (22) PCT Filed: May 5, 2006 R \ / (86). PCT No.: PCT/USO6/17412 S371 (c)(1), (2), (4) Date: May 30, 2008 * / Related U.S. Application Data (60) Provisional application No. 60/677,976, filed on May Pharmaceutical compositions and methods for treating cho 5, 2005. lesterol- and lipid-associated diseases are also disclosed. US 2009/013 1395 A1 May 21, 2009 BPHENYLAZETIONONE CHOLESTEROL autoimmune disorders, (6) an agent used to treat demylena ABSORPTION INHIBITORS tion and its associated disorders, (7) an agent used to treat Alzheimer's disease, (8) a blood modifier, (9) a hormone FIELD OF THE INVENTION replacement agent/composition, (10) a chemotherapeutic 0001.
    [Show full text]